Clinical Trial Update: Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors [Phase 1, Phase 2]

View source ↗

Summary

A combined CDK4/6 inhibitor and PD-L1 monoclonal antibody trial across Phase 1 and Phase 2 for digestive system tumors; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Cancer

Snippet

Sponsor: Peking University | Conditions: Digestive System Tumors | Phase 1, Phase 2 | Status: UNKNOWN